Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Abstract Background Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal events in type 2 diabetes mellitus (DM) patients. However, no study to date...

Full description

Bibliographic Details
Main Authors: Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Eriko Abe, Hiromichi Wakui, Kouichi Tamura
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitors
GLP-1 receptor agonist
Meta-analysis
Cardiovascular disease
Renal outcomes
Diabetes mellitus
Online Access:https://doi.org/10.1186/s12933-020-01197-z

Internet

https://doi.org/10.1186/s12933-020-01197-z

Similar Items